Clinical Trial Update: Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen [Phase 4]

View source ↗

Summary

Phase 4 trial comparing injection frequency between aflibercept and ranibizumab in central retinal vein occlusion using a treat-and-extend regimen.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Retinal Vein Occlusion

Drugs mentioned

• Aflibercept (Aflibercept)
• Ranibizumab (ranibizumab)

Snippet

Sponsor: Anders Kvanta | Conditions: Central Retinal Vein Occlusion | Phase 4 | Status: COMPLETED